New Drugs and Diet Changes Are Reshaping Treatment for a Rare Kidney Disease
FSGS, a scarring kidney disease affecting 40,000+ Americans, now has expanding treatment options including a newly approved dual-action drug.
Summary
Focal segmental glomerulosclerosis (FSGS) is a rare, progressive kidney disease that causes scarring of the kidney's filtering units and leads to protein leakage in urine, often ending in kidney failure. With no cure available, doctors have relied on steroids and immune-suppressing drugs with limited success. That's changing. A newly approved drug called sparsentan targets two key receptors simultaneously to reduce protein loss, and some nephrologists are already shifting it to first-line therapy. Beyond drugs, dietary adjustments can also help manage proteinuria. Looking ahead, APOL1 inhibitors and CCR2 pathway inhibitors represent a new wave of targeted therapies under investigation. Experts describe this moment as a renaissance for kidney disease treatment.
Detailed Summary
Focal segmental glomerulosclerosis (FSGS) is a rare but serious kidney disease in which the kidney's microscopic filtering structures — the glomeruli — become scarred, causing chronic protein leakage into urine. This proteinuria drives progressive kidney damage and frequently leads to end-stage renal disease requiring dialysis or transplant. More than 40,000 Americans are estimated to be affected, and until recently, treatment options were limited and inconsistently effective.
Current standard treatments fall into two broad categories: immunosuppressive and non-immunosuppressive. Immunosuppressants like high-dose corticosteroids and calcineurin inhibitors are first-line for primary FSGS, but response rates are modest — studies suggest only 50–69% of patients respond to steroids. Non-immunosuppressive options such as SGLT2 inhibitors, ACE inhibitors, and angiotensin receptor blockers help lower pressure inside the glomeruli and reduce protein loss.
A significant development is the recent approval of sparsentan (Filspari) for FSGS in patients aged 8 and older who do not have full nephrotic syndrome. The drug works by blocking both endothelin A and angiotensin II receptors, offering a dual mechanism that targets the disease more precisely. At least one leading nephrologist at NYU Langone is already incorporating sparsentan as a first-line option for appropriate patients, particularly those with non-nephrotic range proteinuria.
On the horizon, researchers are investigating APOL1 inhibitors — relevant to a genetic variant that increases FSGS risk in people of African ancestry — and CCR2 pathway inhibitors, which target inflammatory mechanisms driving kidney scarring. These represent a shift toward precision medicine in nephrology, addressing specific molecular causes rather than broadly suppressing the immune system.
Caveats remain: FSGS is heterogeneous, and treatment must be tailored to whether the disease is primary, secondary, or of undetermined origin. Immunosuppression is actively discouraged in secondary forms. Clinical trial data for emerging agents is still maturing, and real-world outcomes will take time to confirm.
Key Findings
- Sparsentan, newly approved for FSGS, targets both endothelin A and angiotensin II receptors to reduce proteinuria.
- Steroid response rates in FSGS range from only 50–69%, highlighting the need for better treatment options.
- SGLT2 inhibitors and RAAS blockers offer non-immunosuppressive proteinuria reduction with established safety profiles.
- APOL1 and CCR2 inhibitors are emerging as precision therapies targeting FSGS-specific molecular pathways.
- Dietary changes alongside drug therapy can help reduce proteinuria and slow kidney disease progression.
Methodology
This is a clinical news report from MedPage Today, a credible medical journalism outlet targeting healthcare professionals. It draws on expert commentary from nephrologists at Mount Sinai, Johns Hopkins, and NYU Langone, and references KDIGO clinical guidelines and a 2016 peer-reviewed review. No primary study data is presented directly.
Study Limitations
The article is expert opinion and commentary rather than a summary of a specific new clinical trial, limiting the strength of evidence presented. Treatment recommendations vary significantly based on FSGS subtype, and personalized clinical judgment is essential. Readers should consult primary KDIGO guidelines and trial registries for the latest evidence on pipeline therapies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: